Vistagen Therapeutics, Inc. Balance Sheet
VTGN|8 years of annual SEC 10-K data (FY2011-FY2023)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
Vistagen Therapeutics, Inc. had $21M in total assets and $65M in shareholders' equity as of FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.6M | $68.1M | $1.4M | $2.9M | $428.5K | $638.1K | $81.0K | $139.3K |
| Current Assets | $17.5M | $71.0M | $104.1M | $11.0M | $3.4M | $671.8K | $238.1K | $238.1K |
| PP&E (Net) | $507.3K | $414.3K | $367.4K | $207.4K | $286.5K | $180.7K | $74.5K | $74.5K |
| Total Assets | $21.1M | $74.6M | $108.3M | $11.3M | $3.7M | $881.5K | $341.6K | $341.6K |
| Current Liabilities | $4.6M | $5.8M | $4.2M | $1.5M | $1.4M | $2.4M | $3.2M | $3.2M |
| Total Debt | - | - | - | - | - | $2.1M | - | - |
| Shareholders' Equity | $64.7M | $92.0M | -$5.7M | $615.8K | -$3.0M | -$12.6M | -$32.9M | -$225.5K |